- Home
- CSX vs MDT Comparison
CSX vs MDT Comparison
Compare CSX & MDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSX | MDT |
|---|---|---|
| Founded | 1978 | 1949 |
| Country | United States | Ireland |
| Employees | 23000 | N/A |
| Industry | Railroads | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4B | 105.3B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CSX | MDT |
|---|---|---|
| Price | $46.11 | $80.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 21 |
| Target Price | $43.05 | ★ $108.21 |
| AVG Volume (30 Days) | ★ 11.5M | 11.0M |
| Earning Date | 04-22-2026 | 06-03-2026 |
| Dividend Yield | 1.25% | ★ 3.58% |
| EPS Growth | N/A | ★ 3.32 |
| EPS | 0.43 | ★ 3.73 |
| Revenue | $10,636,000,000.00 | ★ $36,364,000,000.00 |
| Revenue This Year | $4.58 | $8.91 |
| Revenue Next Year | $4.89 | $6.54 |
| P/E Ratio | $107.37 | ★ $21.61 |
| Revenue Growth | ★ 17.64 | 8.43 |
| 52 Week Low | $31.80 | $73.31 |
| 52 Week High | $48.03 | $106.33 |
Technical Indicators
Market Signals| Indicator | CSX | MDT |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 52.98 |
| Support Level | $44.51 | $73.85 |
| Resistance Level | $46.51 | $82.83 |
| Average True Range (ATR) | 0.99 | 1.70 |
| MACD | -0.18 | 0.19 |
| Stochastic Oscillator | 34.33 | 52.50 |
Price Performance
Historical ComparisonAbout CSX CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue of nearly $14 billion in 2025. On its more than 21,000 miles of track, CSX hauls shipments of coal (16% of consolidated revenue), chemicals (17%), intermodal containers (16%), automotive cargo (7%), and a diverse mix of other bulk and industrial merchandise.
About MDT Medtronic plc.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.